Biotechnology & Immunology


Sterile CAR-T cell lines for faster leukaemia research


Amsbio is helping researchers fast-track CAR-T cell therapy development with a growing portfolio of experimental cell lines, recombinant proteins, and screening services.


CAR-T therapy reached a key milestone in 2017 when the FDA approved its use for children and adolescents with B cell acute lymphoblastic leukaemia (ALL). Since then, research has expanded to explore CAR-T cells targeting multiple B cell proteins, improving anti-tumour activity, reducing relapse caused by antigen escape, and tackling tumour heterogeneity.


“Amsbio’s ready-to-use CAR-T cell lines are designed to support this cutting-edge research,” said Dr Maja Petkovic, Business Development Manager. “Our portfolio includes knockout lines for TCR, B2M, and CIITA, allowing scientists to model universal CAR-T cells. We also provide sterile, pathogen- and mycoplasma-free lines expressing key CAR targets such as BCMA, CD19, CD20, and CD22, many equipped with luciferase reporters for easy monitoring.”


Dr Petkovic added: “Researchers can now access CAR-expressing cells ready for assay design, optimisation, and use as positive controls in co-culture experiments. We also offer bispecific CAR-T cells targeting CD19 & CD22, supporting the development of next-generation therapies.”


For further details on ready-to-use sterile cell lines for CAR-T therapy research please contact Amsbio. More information online: ilmt.co/PL/wG00


65822pr@reply-direct.com


Next-generation medium optimises CHO cell productivity


Thermo Fisher Scientific has launched Gibco™ Efficient-Pro™ Medium (+) Insulin, a next-generation medium designed to enhance protein production and streamline workflows for insulin-dependent CHO cell lines. The medium delivers up to 61% higher protein titres compared with alternatives while supporting high viable cell densities and robust growth without compromising product quality.


Efficient-Pro Medium (+) Insulin is compatible with a broad range of insulin-dependent CHO cell lines and comes in flexible packaging formats, including a dry media version using Advanced Granulation Technology™ (AGT™) for rapid reconstitution and scalability. Its animal origin–free (AOF) formulation reduces process variability and simplifies regulatory compliance, providing researchers and manufacturers with greater confidence in reproducible results.


Ideal for developers of monoclonal antibodies, bispecifics, and Fc-fusion proteins, the medium offers consistent growth and production conditions, reducing variability and supporting streamlined process development.


“Our Efficient-Pro Medium (+) Insulin addresses key industry challenges by combining AGT dry format with an AOF formulation,” said Sara Henneman, VP and GM of Thermo Fisher’s cell culture and cell therapy business. “It enables reliable, high-performance production while supporting the development of innovative therapies.”


As the biologics industry demands faster development timelines, lower costs, and greater supply chain agility, this medium eliminates the need for manual insulin supplementation and helps ensure consistent, high-quality bioprocessing.


“With this launch, we’re helping customers scale rapidly, adapt to evolving project needs, and accelerate the delivery of life-changing therapies,” added Andy Campbell, Senior Director of R&D at Thermo Fisher Scientific.


More information online: ilmt.co/PL/JoYZ 65823pr@reply-direct.com


Defi ned medium for scalable production of stem cell-derived vesicles


A defined, xeno-free culture medium from Takara Bio Europe is opening new possibilities for large-scale production of extracellular vesicles (EVs) from human mesenchymal stem cells (MSCs) - a critical step toward developing next-generation cell-free therapies.


The Cellartis® MSC EV Wonder™ medium enables researchers to achieve up to nine times higher EV yields than conventional DMEM, while preserving key biological characteristics such as CD marker expression, morphology, and RNA cargo profiles.


As interest in MSC-derived EVs grows due to their regenerative and immunomodulatory potential, scalable and reproducible manufacturing has become a central challenge. Traditional culture systems often produce inconsistent vesicle quality or insufficient yields for translational research.


“Cellartis MSC EV Wonder was designed around a chemically defined supplement that eliminates variability and maintains essential MSC-EV features, ensuring reproducibility and simplifying the move toward GMP manufacturing,” explained Clemence Bonhomme, Scientist at Takara Bio Europe.


The medium’s phenol red–free formulation is compatible with Takara Bio’s Cellartis MSC Xeno-Free Culture System, allowing researchers to transition smoothly from MSC expansion to EV harvest.


“Reliable production of high-quality MSC-EVs has been a bottleneck for the field,” added Dr Tarik Hadi, Senior Market Strategy Manager. “With MSC EV Wonder, we’re providing a solution that strengthens quality control, streamlines workflows, and accelerates translation from discovery to clinical development.”


More information online: ilmt.co/PL/eqLB 66052@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64